Displaying 1 to 15 of 15 investments
| Company | Country | Date | Notes | ||
|---|---|---|---|---|---|
|
Addex Pharmaceuticals SA Switzerland-based drug company focused on CNS disorders |
Switzerland | N/A Active |
||
|
|
Aileron Therapeutics Inc Developing a breakthrough proprietary peptide technology platform |
United States | N/A Active |
||
|
|
Alnylam Pharmaceuticals Inc |
United States | N/A |
||
|
|
Ambit Biosciences Inc A biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. |
United States | 10 Jun 2011 | Series D |
|
|
|
Conatus Pharmaceuticals Inc Biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. |
United States | N/A |
||
|
|
CytomX Therapeutics Developer of proteolytically-activated antibodies |
United States | Series B |
||
|
|
Halozyme Therapeutics Inc Biopharmaceutical company developing & commercializing products targeting the extracellular matrix. |
United States | N/A |
||
|
Horizon Discovery Ltd |
United Kingdom | 3 Jun 2013 | Series C Round participant. Active |
|
|
|
Horizon Discovery Ltd |
United Kingdom | 16 Jan 2012 | Series C Round participant. Active |
|
|
|
Inimex Pharmaceuticals Inc |
Canada | 1 Jun 2008 | Series B |
|
|
|
Intradigm Corp |
United States | N/A |
||
|
|
IRX Therapeutics Inc |
United States | N/A |
||
|
|
Nereus Pharmaceuticals Inc |
United States | 1 Aug 2007 | Series D |
|
|
|
Nereus Pharmaceuticals Inc |
United States | 1 Jun 2010 | Series E |
|
|
|
Opsona Therapeutics Ltd Innate immune drug development company |
Ireland | 29 Apr 2013 | Series C Active |